Solid Tumor Program Medical Director Associate or Professor of Clinical Pediatrics (Hematology-Oncology)-CHLA

The University of Southern California (USC), founded in 1880, is the largest private employer in the City of Los Angeles. As an employee of USC, you will be a part of a world-class research university and a member of the "Trojan Family," which is comprised of the faculty, students and staff that make the university what it is.

The Cancer and Blood Disease Institute (CBDI) at the Children’s Hospital Los Angeles (CHLA) and the Division of Hematology-Oncology within the Department of Pediatrics, Keck School of Medicine, University of Southern California (USC) are recruiting an internationally recognized leader to serve as the Medical Director of the Solid Tumor Program. This individual will oversee clinical and research activities, and work with CBDI leadership on Program expansion. They will be expected to conduct research and further advance a leading research program that integrates laboratory and clinical science to develop and deliver innovative cancer therapies for pediatric solid tumors. The position reports to the CBDI Section Head for Oncology. The position includes membership at the USC Norris Comprehensive Cancer Center and an academic appointment through USC Keck School of Medicine at the level of Associate Professor or Professor, appropriate to training and experience.

The CBDI is the largest and top-ranked pediatric hematology-oncology program in the western U.S. The U.S. News & World Report ranked the CBDI #3 and CHLA #7 in the nation in 2023-24. The Solid Tumor Program saw approximately 100 new patients in 2022. The Program is dedicated to providing the best possible multidisciplinary, individualized care for children with solid tumors including sarcomas, neuroblastoma, retinoblastoma, liver tumors, and kidney tumors. The Program conducts leading-edge research to discover, develop and deliver therapies designed to improve outcomes. The CBDI has a large clinical trials operation. Two leading, international pediatric oncology clinical trials consortia are headquartered within the CBDI: New Approaches to Neuroblastoma Therapy (NANT) and the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL). The CBDI is also an active member of 20 leading international consortia. CBDI investigators conduct extensive bench-to-bedside research. Research funding in FY23 totaled $52.5 million with $8.3 million in new awards. The CBDI hosts an ACGME-accredited pediatric hematology-oncology fellowship training program and 1-year advanced subspecialty fellowships in AYA Oncology, Neuro-Oncology, Transplantation/Cellular Therapy and Coagulation.

The annual base salary range for this position is $116,505-$517,500.  When extending an offer of employment, the University of Southern California considers factors such as (but not limited to) the scope and responsibilities of the position, the candidate’s work experience, education/training, key skills, internal peer equity, federal, state, and local laws, contractual stipulations, grant funding, as well as external market and organizational considerations.

Strong administrative, clinical, research and financial support will be provided, including staff, infrastructure, endowments, and institutional resources. CHLA and USC are equal opportunity, affirmative action employers. The division greatly values diversity and is committed to building a vibrant and culturally diverse community of faculty that best reflects the patients and families we serve. Individuals from underrepresented groups in medicine are especially encouraged to apply.

For inquiries, please contact:

Alan S. Wayne, M.D.

Director, Cancer and Blood Disease Institute

Chief, Division of Hematology-Oncology

Vice Chair, Department of Pediatrics

Children's Hospital Los Angeles

Associate Director, USC Norris Comprehensive Cancer Center

Professor of Pediatrics and Medicine

Keck School of Medicine

University of Southern California

Alfred E. Mann Family Foundation Chair in Cancer Research

awayne@chla.usc.edu